+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

CLL Clinical Scholar Award

CLL (Chronic Lymphocytic Leukemia) Society

Goal: This award is dedicated to exceptional physician researchers who have already established themselves in the field of CLL / SLL. It is designed to support the research efforts of an advanced physician-scientist who is engaged in independent clinical research and has demonstrated exceptional leadership, scholarship, and academic success. The Clinical Scholar Award is intended to advance the development of treatment and/or preventative options for those living with CLL / SLL while continuing to support the careers of established physician-scientists. The proposal must focus exclusively on CLL / SLL and/or directly related disorders.

Applicant Requirements: Researchers must be an MD, DO, or the equivalent who is an independent clinician investigator. Clinical Scholar Award applicants should be mid-stage in their career (defined as being someone who is either an associate professor, or within five years or less from acquiring full professorship as of the funding date of July 1st, 2026). Applicants must have a strong focus on CLL research and/or treatment. Please see the RFP for additional details about applicant requirements.

Term of Award: Three years.

Budget: $300,000, which will be distributed into three annual payments of $100,000.

AI Based Application Success Predictor

1️⃣ Clear, Direct Relevance to CLL (Most Important)

Proposals must explicitly focus on:

CLL/SLL biology

CLL-specific therapeutic targets

CLL disease mechanisms (microenvironment, BCR signaling, clonal evolution)

Response/resistance to BTK inhibitors, BCL2 inhibitors, PI3K inhibitors

Real-world treatment complications unique to CLL (infections, immune dysfunction)

Predictor: Strong CLL specificity — not general leukemia or lymphoma research.

2️⃣ High Patient Impact, Especially in the Near-to-Mid Term

The Society is patient-driven, prioritizing outcomes that improve:

Survival

Quality of life

Treatment selection and sequencing

Toxicity reduction

Patient education and decision-making

Management of comorbidities or infection risk

Access to high-quality care

Predictor: Clear benefit to people living with CLL.

3️⃣ Translational Potential & Clinical Relevance

Strong proposals describe:

How mechanistic findings could lead to new therapies

Biomarker development for predicting response or relapse

Models that reflect real-world CLL biology (primary patient samples, ex vivo culture, single-cell analysis)

Research that could advance to clinical trials or practice changes

Predictor: A well-articulated bench → bedside pathway.

4️⃣ High-Value Focus Areas (Consistent with Recent Funded Projects)

Successful applications often address:

Mechanisms of resistance to BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib)

Venetoclax resistance biology

Targeting microenvironmental survival signals

Novel cellular therapies (CAR-T, NK, bispecific antibodies)

Minimal residual disease (MRD) detection & MRD-guided treatment

Mutation-guided therapy (IGHV, TP53, NOTCH1, SF3B1, BIRC3, etc.)

Real-world outcomes and disparities

Immune dysfunction, infection prevention, and vaccine response

Predictor: Alignment with CLL’s most pressing clinical and biological challenges.

5️⃣ Strong Preliminary Data

Most funded CLL proposals include:

Pilot mechanistic data

Early patient-sample analyses

Feasibility studies for cohort enrollment or tissue access

Proof-of-concept results for biomarker or therapeutic ideas

Predictor: Proposals supported by solid preliminary data outperform speculative ones.

6️⃣ Strong Team, Expertise, & Environment

Reviewers favor:

Investigators with a clear track record in CLL or B-cell malignancies

Access to CLL patients, samples, or clinical trial infrastructure

Expertise in immunology, genomics, computational biology, targeted therapy, or translational oncology

Multi-institutional collaborations (especially where sample numbers are small)

Predictor: Demonstrated ability to execute — not just a strong idea.

7️⃣ Feasibility, Clear Aims, & High-Quality Study Design

The CLL Society looks for:

Realistic 1–2 year aims

Precise endpoints

Appropriate sample size justification

Validated techniques

Risk-mitigation strategies

Scalability for future NIH/DOD funding

Predictor: Well-designed, appropriately scoped pilot studies are highly competitive.

8️⃣ Projects Addressing Care Access, Disparities & Real-World Practice

The Society increasingly funds:

Studies on treatment inequities across geography, race/ethnicity, age, socioeconomic status

Interventions that improve access to clinical trials

Telemedicine models for rural populations

Patient-education improvements for shared decision-making

Real-world data analyses of CLL outcomes

Predictor: Work that improves equity and real-world care has rising importance.

9️⃣ Quality-of-Life, Supportive Care & Survivorship Research

Given CLL is often a long-lived disease, the Society values:

Palliative/supportive care innovations

Management of fatigue, immune suppression, infections

Patient decision-making around therapy sequencing

Survivorship tools and resources

Predictor: Proposals improving lived experience and patient empowerment score well.

🚫 COMMON PITFALLS (Why CLL Society Applications Fail)

Pitfall	Why It Hurts
Not specifically focused on CLL	Misaligned with mission
Very basic science with no translational pathway	Lacks patient relevance
Overly ambitious project	Not feasible for pilot-scale funding
Weak or absent preliminary data	Too speculative
No access to patient samples or clinical infrastructure	Feasibility concerns
Generic leukemia/lymphoma study	Not CLL-specific
No mention of patient benefit or QOL	Fails patient-centered criteria
Poor justification for methods	Reviewer uncertainty

Specialties

Cancer

Neurosciences

Eligibility Requirements

Please thoroughly read the RFP document for the grant you are applying for, as there is additional eligibility information that is specific to each individual grant. The RFP can be found on the Current Funding Opportunities page. General eligibility requirements that are specific to all CLL Society grants include:

The research must be conducted at a non-profit academic institution located within the United States.
Applicants must be directly associated with a sponsoring institution or fiscal agent to receive grant funding, as CLL Society funding must be paid directly to the academic institution and not the researcher.
Adjustments for career interruptions can be made. These could include but are not limited to family leave, military service, major illness, or injury. It will be the responsibility of the awardee to document such interruptions and notify CLL Society’s Research Program Administrator as soon as possible should any interruptions occur.
The awardee must agree to acknowledge CLL Society in any publications or presentations that result from the funding.
The awardee must agree to provide annual Scientific Progress Reports and annual Financial Reports as will be outlined within the award agreement. this document will be provided to the academic institution for review and signatures after the awardee has been selected.
Previous recipients of CLL Society research funding are eligible to re-apply. However, awardees cannot have concurrent funding from CLL Society for more than one type of CLL Society grant at any given time.
Applicants are allowed to submit one application per award type per year. Should more than one proposal be selected by each Research Review Committee in any given year, only one award will be allowed for funding. The applicant will be asked to choose which grant type they would like to receive funding for at the prompting of the Research Review Committee.

Ineligible:

Research that would be performed outside of the United States.
Applicants should only submit one letter of intent per CLL Society award type in any given year. Submitting multiple letters of intent for the same type of award in any given year will result in automatic disqualification. Individuals will be allowed to submit one application per award type, but will only be awarded one.
Industry-sponsored clinical trials are not allowed.

Sponsor Details

Sponsor Institute/Organizations: CLL (Chronic Lymphocytic Leukemia) Society

Sponsor Type: Corporate/Non-Profit

Address: 450 Rev Kelly M Smith Way Nashville, TN 37203

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity